Perimeter Medical Imaging AI develops real-time optical coherence tomography imaging systems and artificial-intelligence tools for cancer surgery. The company’s Claire OCT+AI device has FDA premarket approval for intraoperative breast cancer margin assessment, while its S-Series OCT platform provides ultra-high-resolution cross-sectional visualization of excised tissue.
Company news commonly covers FDA regulatory milestones, product demonstrations, commercialization activity, clinical and technology updates, operating and financial results, investor conference presentations, and capital-structure actions such as private placements, warrants, and stock-option matters.
Perimeter Medical Imaging AI (TSXV: PINK) (OTC: PYNKF) has closed a non-brokered private placement, issuing 23,470,560 common shares at $0.42 per share, raising gross proceeds of $9,857,635. The company may complete additional closings for up to $13.5 million in total. Social Capital, led by Chamath Palihapitiya, was the lead investor, purchasing 14,507,453 shares. The funds will support the U.S. commercial adoption of Perimeter's FDA-cleared S-Series OCT and advance the development of their B-Series OCT system with AI technology. The offering also included participation from company insiders and early investors.
Perimeter Medical Imaging AI (TSXV: PINK) (OTC: PYNKF) has announced a non-brokered private placement of up to 32,175,032 common shares at $0.42 per share, aiming to raise up to $13.5 million. The company has secured binding agreements for approximately $9.7 million, including from its largest shareholder, Social Capital. The closing is expected around September 20, 2024, subject to conditions including TSXV approval. Proceeds will be used for working capital, commercialization, clinical studies, and technology development. The offering includes a four-month hold period and may involve cash commissions to finders. Social Capital's participation constitutes a 'related party transaction' under MI 61-101, with the company relying on exemptions from formal valuation and minority shareholder approval requirements.
Perimeter Medical Imaging AI reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- 83% revenue growth in Q2 2024 compared to Q2 2023
- Six new S-Series OCT system placements year-to-date, up from three in all of 2023
- Anticipated completion of patient enrollment for B-Series OCT pivotal trial in Q3 2024, earlier than expected
- White paper showing lower reoperation rates with Perimeter S-Series OCT compared to national averages
- 1,000th paid Perimeter S-Series OCT patient scan milestone achieved
- Introduction of ImgClear AI image enhancement algorithm
Financial results: Q2 2024 revenues of $246,000, net loss of $3.2 million (improved 35% YoY), and cash position of $6.5 million as of June 30, 2024.
Perimeter Medical Imaging AI (TSXV: PINK, OTC: PYNKF, FSE: 4PC) has announced it will report its second quarter 2024 financial and operating results after market close on Wednesday, August 14, 2024. Following the announcement, the company's management will host a webcast and conference call to discuss the results and provide a corporate update.
The conference call is scheduled for 5:00 pm Eastern Time on August 14, 2024. Investors can dial in using the following numbers: 1-800-717-1738 (Canada and the United States) or 1-646-307-1865 (International). The call will also be broadcast live and archived on the company's website under the 'News/Events' section in the Investors area.
Perimeter Medical Imaging AI will host an investor webcast on June 25, 2024, at 2:00 PM ET. The event will feature presentations from CEO Adrian Mendes, CIO Andrew Berkeley, and CFO Sara Brien, focusing on key business areas. Investors can engage in a live Q&A session. To participate, pre-register at the provided link. An archived version will be accessible on the company's website.
Perimeter Medical Imaging AI reported its Q1 2024 financial results, highlighting significant progress in clinical development and commercial expansion.
The company exceeded patient enrollment expectations in its pivotal clinical trial for the B-Series OCT with ImgAssist AI, leading to a decision to expedite full enrollment by early Q4 2024. Three new placements of the S-Series OCT system were completed, boosting market presence.
Financially, operating expenses rose to $4.7 million, but net loss decreased to $2.1 million compared to Q1 2023. Cash and equivalents stood at $10.6 million as of March 31, 2024.
A conference call is scheduled for 5 pm ET to discuss the results and provide further updates.
Perimeter Medical Imaging AI, Inc. (PYNKF) will release its first quarter 2024 financial results on May 14, 2024, followed by a conference call hosted by CEO Adrian Mendes. The call will discuss the results and provide a corporate update. Investors can join the call online or via phone.
Summary not available.
Summary not available.
Summary not available.